Elomotecan

• Description:

  Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT) . Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II[1].

• Product Name Alternative:

  BN 80927 (free base)

• UNSPSC:

  12352005

• Target:

  Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/elomotecan.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=C(CN5CCC(C)CC5)C6=CC(C)=C(Cl)C=C6N=C4C3=C2)=O

• Molecular Formula:

  C29H32ClN3O4

• Molecular Weight:

  522.04

• References & Citations:

  [1]Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70 (2) :239-250.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  Topo I; Topo II

• CAS Number:

  [220998-10-7]